Results 201 to 210 of about 707,795 (309)

Impact of extended insurance coverage on survival outcomes among patients with metastatic colorectal cancer in Taiwan

British Journal of Clinical Pharmacology, EarlyView.
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang, Chen‐Han Chueh, Chien‐Yu Tseng, Christopher N. Kaufmann, Earl J. Morris, Chiao‐En Wu, Yi‐Wen Tsai   +6 more
wiley   +1 more source

Desirable insurance coverage for electronic mental health services: a qualitative study on perspectives and preferences of university students and menta. [PDF]

BMC Health Serv Res
Nastaran A, Ramezani-Doroh V, Khoramrooz M, Rangchian M.   +3 more
europepmc   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

The Role of Medicare Insurance Coverage Type in Annual Wellness Visits: A Comparison between Traditional Medicare and Medicare Advantage Plan [PDF]

Alzheimers Dement
Zhang Z.
europepmc   +2 more sources

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Understanding insurance coverage policies for incretin mimetics for weight management. [PDF]

Am J Manag Care
Griauzde DH, Carter EW, Oshman L, Gabison J, Kraftson A, Fendrick AM, Lott S.   +6 more
europepmc   +1 more source

Do drugs approved via expedited approval pathways have therapeutic advantages? A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Regulators use expedited approval pathways to speed market approval and patient access to promising new drugs. However, there is uncertainty about whether these pathways are successful in approving drugs with significant therapeutic advantages. This systematic review aims to examine the safety, effectiveness and cost‐effectiveness of drugs approved via
Ashleigh Hooimeyer, Eliza J. McEwin, Zhicheng Wang, Joel Lexchin, Barbara Mintzes   +4 more
wiley   +1 more source

Expanding Insurance Coverage for Pediatric Upper Extremity Recreational Prosthetic Devices. [PDF]

J Hand Surg Glob Online
Lazar S, Eggert GR, Reghunathan M, Hinchcliff KM.   +3 more
europepmc   +1 more source

Impact of secured prescription implementation on ambulatory pregabalin use in France: A regional assessment in the French Nouvelle‐Aquitaine

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The French authorities mandated the use of secure prescriptions for pregabalin on May 2021. This study aimed to evaluate the impact of this measure on pregabalin use and misuse in Nouvelle‐Aquitaine, a southwestern French region with around six million inhabitants.
Maika Munech‐Herran, Véronique Moysan, Bruno Lescarret, Clément Mathieu, Antoine Pariente, Nicolas Rousselot   +5 more
wiley   +1 more source